Friday, 03 Apr 2020

You are here

Belimumab in Lupus Nephritis

Belimumab has been studied in an active lupus nephritis, phase 3 trial call BLISS-LN and shown to be effective as measured by  trial of belimumab for the treatment of active lupus nephritis in adult patients.

This 2 year randomized, double-blind, placebo-controlled trial compared the efficacy and safety of belimumab 10mg/kg intravenous (IV) versus placebo in patients receiving backgrou standard therapy (mycophenolate mofetil for induction and maintenance, or cyclophosphamide for induction followed by azathioprine for maintenance, plus steroids)

A total of 448 adult patients with lupus nephritis were treated and the primary endpoints was renal response (PERR), defined as eGFR ≥60mL/min/1.73m2 or no decrease in eGFR from pre-flare of >20%; and urinary protein: creatinine ratio (uPCR) ≤0.7; and not a treatment failure. 

The results showed belimumab to be superior to placebo with significantly more patients achieving a renal response over over 2 years (43% vs 32%; P =.0311).

With regard to safety, adverse events were observed to be similar between the belimumab and placebo groups and consistent with the safety profile for belimumab. 

Belimumab also superior to placebo for secondary endpoints: Complete Renal Response (CRR), and time to death or renal-related event.

Benlysta is currently not recommended, nor approved for use in severe active lupus nephritis.

The full results will be submitted for future presentation at upcoming scientific meetings and in peer-reviewed publications.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

In Lupus, Keep BP Below 130/80

Blood pressure should be maintained at a level below 130/80 mm Hg in all patients with lupus to lessen their likelihood of atherosclerotic vascular events, Canadian researchers asserted.

In Vasculitis, Beware of Infection

Risks of infection were strikingly high among patients with antineutrophil cytoplasmic antibody-associated (ANCA) vasculitis, which may relate to both the disease and its treatment, Scottish researchers found.

Malignancies with Giant Cell Arteritis

The Journal of Rheumatology reports the findings of a Swedish population-based cohort study of biopsy-proven giant cell arteritis (GCA) patients showing that the overall risk for cancer was not increased; yet there appears to be an increased risk for leukemia and a decreased risk for breast and upper gastrointestinal tract cancers.   

Hospitalized GPA - Higher morbidity, Mortality and Cost

Rheumatology reports on a study of patients with granulomatosis with polyangiitis (GPA) showing worse outcomes and higher costs when hospitalized with GPA.

GPA patients were identified from the Nationwide Inpatient Sample (NIS) and were compared to those without GPA with regard to demographics, procedures, length of stay, mortality, morbidity and total hospitalization charges (between 2005–2014).

Don't Blame the Weather in Sjogren's

Seasonal variations in symptoms -- commonly reported by patients with rheumatic diseases -- were not observed in a large cohort of patients with primary Sjogren's syndrome, French investigators found.